Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant

Rhea-AI Filing Summary

Regnante Keith reported acquisition or exercise transactions in this Form 4 filing.

Keros Therapeutics reported that its Chief Financial Officer, Keith Regnante, received a grant of stock options covering 60,000 shares of common stock. These options were awarded as an employee stock option grant at a stated price per share of $0.0000.

According to the terms, one-fourth of the options will vest on February 24, 2027, and the remaining options will vest in twelve substantially equal quarterly installments after that date, as long as he continues to provide service through each vesting date. After this award, he holds 60,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Regnante Keith

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	60,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 60,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Regnante Keith

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$15.52	02/24/2026		A		60,000		(1)	02/23/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Keith Regnante	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Keros Therapeutics (KROS) disclose for Keith Regnante?

Keros Therapeutics disclosed that Chief Financial Officer Keith Regnante received a grant of employee stock options for 60,000 shares. These options were reported as a derivative acquisition under code "A," reflecting a grant, award, or other acquisition rather than an open-market purchase or sale.

How many Keros Therapeutics (KROS) stock options were granted to the CFO?

The CFO of Keros Therapeutics was granted employee stock options covering 60,000 shares of common stock. Following this grant, the Form 4 shows he directly holds 60,000 derivative securities, reflecting the full amount of the newly awarded options in his reported holdings.

What is the vesting schedule for the 60,000 Keros Therapeutics (KROS) options?

The 60,000 options vest over time, with one-fourth vesting on February 24, 2027. The remaining options vest in twelve substantially equal quarterly installments thereafter, provided Keith Regnante continues to provide service through each scheduled vesting date, creating a multi-year, service-based vesting structure.

Was the Keros Therapeutics (KROS) CFO transaction a buy or sell in the market?

The transaction was not a market buy or sell; it was a stock option grant. The filing classifies it under transaction code "A" as a grant, award, or other acquisition, with zero reported buy or sell share counts in the transaction summary section.

What ownership type is reported for the Keros Therapeutics (KROS) stock options?

The Form 4 indicates that the 60,000 employee stock options are held with direct ownership. The filing lists the ownership type and code as direct ("D"), with no separate entity or indirect ownership structure described in the provided information for this specific option grant.

When do the newly granted Keros Therapeutics (KROS) options start vesting?

The options begin vesting on February 24, 2027, when one-fourth of the 60,000-share grant is scheduled to vest. After that initial date, the remaining options vest in twelve substantially equal quarterly installments, conditioned on continued service to the company at each vesting point.